Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
Identifieur interne : 001335 ( Main/Corpus ); précédent : 001334; suivant : 001336Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
Auteurs : H. Heinonen ; M. Savij Rvi ; M. Kotila ; A. Hajba ; M. ScheininSource :
- Journal of Neural Transmission - Parkinson's Disease and Dementia Section [ 0936-3076 ] ; 1993-10-01.
Abstract
Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.
Url:
DOI: 10.1007/BF02257674
Links to Exploration step
ISTEX:09AACF3CE7AC45D5646858190481A17203A07677Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><author><name sortKey="Heinonen, H" sort="Heinonen, H" uniqKey="Heinonen H" first="H." last="Heinonen">H. Heinonen</name><affiliation><mods:affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Savij Rvi, M" sort="Savij Rvi, M" uniqKey="Savij Rvi M" first="M." last="Savij Rvi">M. Savij Rvi</name><affiliation><mods:affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kotila, M" sort="Kotila, M" uniqKey="Kotila M" first="M." last="Kotila">M. Kotila</name><affiliation><mods:affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Hajba, A" sort="Hajba, A" uniqKey="Hajba A" first="A." last="Hajba">A. Hajba</name><affiliation><mods:affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Scheinin, M" sort="Scheinin, M" uniqKey="Scheinin M" first="M." last="Scheinin">M. Scheinin</name><affiliation><mods:affiliation>Department of Pharmacology, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:09AACF3CE7AC45D5646858190481A17203A07677</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1007/BF02257674</idno><idno type="url">https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001335</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><author><name sortKey="Heinonen, H" sort="Heinonen, H" uniqKey="Heinonen H" first="H." last="Heinonen">H. Heinonen</name><affiliation><mods:affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Savij Rvi, M" sort="Savij Rvi, M" uniqKey="Savij Rvi M" first="M." last="Savij Rvi">M. Savij Rvi</name><affiliation><mods:affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kotila, M" sort="Kotila, M" uniqKey="Kotila M" first="M." last="Kotila">M. Kotila</name><affiliation><mods:affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Hajba, A" sort="Hajba, A" uniqKey="Hajba A" first="A." last="Hajba">A. Hajba</name><affiliation><mods:affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Scheinin, M" sort="Scheinin, M" uniqKey="Scheinin M" first="M." last="Scheinin">M. Scheinin</name><affiliation><mods:affiliation>Department of Pharmacology, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="ISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1993-10-01">1993-10-01</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="193">193</biblScope><biblScope unit="page" to="202">202</biblScope></imprint><idno type="ISSN">0936-3076</idno></series><idno type="istex">09AACF3CE7AC45D5646858190481A17203A07677</idno><idno type="DOI">10.1007/BF02257674</idno><idno type="ArticleID">Art4</idno><idno type="ArticleID">BF02257674</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0936-3076</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>E. H. Heinonen M. D.</name><affiliations><json:string>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</json:string></affiliations></json:item><json:item><name>M. Savijärvi</name><affiliations><json:string>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>M. Kotila</name><affiliations><json:string>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>A. Hajba</name><affiliations><json:string>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</json:string></affiliations></json:item><json:item><name>M. Scheinin</name><affiliations><json:string>Department of Pharmacology, University of Turku, Turku, Finland</json:string></affiliations></json:item></author><articleId><json:string>Art4</json:string><json:string>BF02257674</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</abstract><qualityIndicators><score>6.565</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 774 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1377</abstractCharCount><pdfWordCount>4237</pdfWordCount><pdfCharCount>23347</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>194</abstractWordCount></qualityIndicators><title>Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><genre><json:string>research-article</json:string></genre><host><volume>5</volume><pages><last>202</last><first>193</first></pages><issn><json:string>0936-3076</json:string></issn><issue>3</issue><subject><json:item><value>Pharmacology/Toxicology</value></json:item><json:item><value>Psychiatry</value></json:item><json:item><value>Neurology</value></json:item></subject><journalId><json:string>722</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1435-1463</json:string></eissn><title>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate></host><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1007/BF02257674</json:string></doi><id>09AACF3CE7AC45D5646858190481A17203A07677</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><availability><p>SPRINGER</p></availability><date>1992-04-21</date></publicationStmt><notesStmt><note>Full Papers</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title><author><persName><forename type="first">E.</forename><surname>Heinonen</surname></persName><roleName type="degree">M. D.</roleName><affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</affiliation></author><author><persName><forename type="first">M.</forename><surname>Savijärvi</surname></persName><affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">M.</forename><surname>Kotila</surname></persName><affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">A.</forename><surname>Hajba</surname></persName><affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</affiliation></author><author><persName><forename type="first">M.</forename><surname>Scheinin</surname></persName><affiliation>Department of Pharmacology, University of Turku, Turku, Finland</affiliation></author></analytic><monogr><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="JournalID">722</idno><idno type="pISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><idno type="IssueArticleCount">9</idno><idno type="VolumeIssueCount">3</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1993-10-01"></date><biblScope unit="volume">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="193">193</biblScope><biblScope unit="page" to="202">202</biblScope></imprint></monogr><idno type="istex">09AACF3CE7AC45D5646858190481A17203A07677</idno><idno type="DOI">10.1007/BF02257674</idno><idno type="ArticleID">Art4</idno><idno type="ArticleID">BF02257674</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992-04-21</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Pharmacology/Toxicology</term></item><item><term>Psychiatry</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992-04-21">Created</change><change when="1993-10-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Vienna</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>722</JournalID><JournalPrintISSN>0936-3076</JournalPrintISSN><JournalElectronicISSN>1435-1463</JournalElectronicISSN><JournalTitle>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</JournalTitle><JournalAbbreviatedTitle>J Neural Transm Gen Sect</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject><JournalSubject Type="Secondary">Psychiatry</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>5</VolumeIDStart><VolumeIDEnd>5</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueArticleCount>9</IssueArticleCount><IssueHistory><CoverDate><DateString>1993</DateString><Year>1993</Year><Month>10</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1993</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art4"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF02257674</ArticleID><ArticleDOI>10.1007/BF02257674</ArticleDOI><ArticleSequenceNumber>4</ArticleSequenceNumber><ArticleTitle Language="En">Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</ArticleTitle><ArticleCategory>Full Papers</ArticleCategory><ArticleFirstPage>193</ArticleFirstPage><ArticleLastPage>202</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2005</Year><Month>11</Month><Day>5</Day></RegistrationDate><Received><Year>1992</Year><Month>4</Month><Day>21</Day></Received><Accepted><Year>1992</Year><Month>10</Month><Day>6</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1993</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>722</JournalID><VolumeIDStart>5</VolumeIDStart><VolumeIDEnd>5</VolumeIDEnd><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" PresentAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>E.</GivenName><GivenName>H.</GivenName><FamilyName>Heinonen</FamilyName><Degrees>M. D.</Degrees></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Savijärvi</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Kotila</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>A.</GivenName><FamilyName>Hajba</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Scheinin</FamilyName></AuthorName></Author><Affiliation ID="Aff2"><OrgDivision>Koskela Hospital, Helsinki</OrgDivision><OrgName>University of Turku</OrgName><OrgAddress><City>Turku</City><Country>Finland</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Department of Pharmacology</OrgDivision><OrgName>University of Turku</OrgName><OrgAddress><City>Turku</City><Country>Finland</Country></OrgAddress></Affiliation><Affiliation ID="Aff1"><OrgName>Orion Corporation FARMOS</OrgName><OrgAddress><Street>R & D Pharmaceuticals</Street><Postbox>P. O. Box 425</Postbox><Postcode>SF-20101</Postcode><City>Turku</City><Country>Finland</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</Para></Abstract><KeywordGroup Language="En"><Heading>Keywords</Heading><Keyword>Selegiline</Keyword><Keyword>noradrenaline</Keyword><Keyword>monoamine metabolites</Keyword><Keyword>monoamine oxidase</Keyword><Keyword>CSF</Keyword><Keyword>Alzheimer's disease</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="given">H.</namePart><namePart type="family">Heinonen</namePart><namePart type="termsOfAddress">M. D.</namePart><affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Savijärvi</namePart><affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Kotila</namePart><affiliation>Koskela Hospital, Helsinki, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Hajba</namePart><affiliation>Orion Corporation FARMOS, R & D Pharmaceuticals, P. O. Box 425, SF-20101, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Scheinin</namePart><affiliation>Department of Pharmacology, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Vienna</placeTerm></place><dateCreated encoding="w3cdtf">1992-04-21</dateCreated><dateIssued encoding="w3cdtf">1993-10-01</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical, effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.</abstract><note>Full Papers</note><relatedItem type="host"><titleInfo><title>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title></titleInfo><titleInfo type="abbreviated"><title>J Neural Transm Gen Sect</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1993-10-01</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Pharmacology/Toxicology</topic><topic>Psychiatry</topic><topic>Neurology</topic></subject><identifier type="ISSN">0936-3076</identifier><identifier type="eISSN">1435-1463</identifier><identifier type="JournalID">722</identifier><identifier type="IssueArticleCount">9</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>1993</date><detail type="volume"><number>5</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="pages"><start>193</start><end>202</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1993</recordOrigin></recordInfo></relatedItem><identifier type="istex">09AACF3CE7AC45D5646858190481A17203A07677</identifier><identifier type="DOI">10.1007/BF02257674</identifier><identifier type="ArticleID">Art4</identifier><identifier type="ArticleID">BF02257674</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1993</recordOrigin></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/09AACF3CE7AC45D5646858190481A17203A07677/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct xml:id="b0"><analytic><title level="a" type="main">Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer's disease</title><author><persName><forename type="first">R</forename><surname>Adolfsson</surname></persName></author><author><persName><forename type="first">Cg</forename><surname>Gottfries</surname></persName></author><author><persName><forename type="first">L</forename><surname>Oreland</surname></persName></author><author><persName><forename type="first">A</forename><surname>Wiberg</surname></persName></author><author><persName><forename type="first">B</forename><surname>Winblad</surname></persName></author></analytic><monogr><title level="j">Life Sci</title><imprint><biblScope unit="volume">27</biblScope><biblScope unit="page" from="1029" to="1034"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct xml:id="b1"><analytic><title level="a" type="main">Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity</title><author><persName><forename type="first">A</forename><surname>Agnoli</surname></persName></author><author><persName><forename type="first">N</forename><surname>Martucci</surname></persName></author><author><persName><forename type="first">G</forename><surname>Fabbrini</surname></persName></author><author><persName><forename type="first">Ae</forename><surname>Buckley</surname></persName></author><author><persName><forename type="first">M</forename><surname>Fioravanti</surname></persName></author></analytic><monogr><title level="j">Dementia</title><imprint><biblScope unit="volume">1</biblScope><biblScope unit="page" from="109" to="114"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b2"><analytic><title level="a" type="main">Changes in dopamine and 2,3-dihy- droxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration</title><author><persName><forename type="first">F</forename><surname>Baraczka</surname></persName></author><author><persName><forename type="first">Mik</forename><surname>Fekete</surname></persName></author><author><persName><forename type="first">B</forename><surname>Kanyicska</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">58</biblScope><biblScope unit="page" from="299" to="304"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b3"><analytic><title level="a" type="main">Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia</title><author><persName><forename type="first">N</forename><surname>Campi</surname></persName></author><author><persName><forename type="first">Gp</forename><surname>Todeschini</surname></persName></author><author><persName><forename type="first">L</forename><surname>Scarzella</surname></persName></author></analytic><monogr><title level="j">Clin Ther</title><imprint><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="306" to="314"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b4"><analytic><title level="a" type="main">Interaction of the tricyclic antidepressant amitriptyline with prejunctional alpha and muscarinic receptors in the dog saphenous vein</title><author><persName><forename type="first">Mg</forename><surname>Collis</surname></persName></author><author><persName><forename type="first">Jt</forename><surname>Shepherd</surname></persName></author></analytic><monogr><title level="j">J Pharmacol Exp Ther</title><imprint><biblScope unit="volume">213</biblScope><biblScope unit="page" from="616" to="622"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct xml:id="b5"><analytic><title></title><author><persName><forename type="first">T</forename><surname>Eisler</surname></persName></author><author><persName><forename type="first">H</forename><surname>Terfivfiinen</surname></persName></author><author><persName><forename type="first">R</forename><surname>Nelson</surname></persName></author><author><persName><forename type="first">H</forename><surname>Krebs</surname></persName></author><author><persName><forename type="first">V</forename><surname>Weise</surname></persName></author><author><persName><forename type="first">Bs</forename><surname>Chem</surname></persName></author><author><persName><forename type="first">Cr</forename><surname>Lake</surname></persName></author><author><persName><forename type="first">Mh</forename><surname>Ebert</surname></persName></author><author><persName><forename type="first">N</forename><surname>Whetzel</surname></persName></author><author><persName><forename type="first">Dl</forename><surname>Murphy</surname></persName></author><author><persName><forename type="first">Ij</forename><surname>Kopin</surname></persName></author><author><persName><forename type="first">Db</forename><surname>Calne</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">31</biblScope><biblScope unit="page" from="19" to="23"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct xml:id="b6"><analytic><title level="a" type="main">Selegiline versus oxiracetam in patients with Alzheimer-type dementia</title><author><persName><forename type="first">A</forename><surname>Falsaperla</surname></persName></author><author><persName><forename type="first">Pam</forename><surname>Preti</surname></persName></author><author><persName><forename type="first">C</forename><surname>Oliani</surname></persName></author></analytic><monogr><title level="j">Clin Ther</title><imprint><biblScope unit="volume">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="376" to="384"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b7"><analytic><title level="a" type="main">Behavioural activities in demented geriatric patients</title><author><persName><forename type="first">L</forename><surname>Ferm</surname></persName></author></analytic><monogr><title level="j">Geront Clin</title><imprint><biblScope unit="volume">16</biblScope><biblScope unit="page" from="185" to="194"></biblScope><date type="published" when="1974"></date></imprint></monogr></biblStruct><biblStruct xml:id="b8"><analytic><title level="a" type="main">L-Deprenyl therapy improves verbal memory in amnesic Alzheimer patients</title><author><persName><forename type="first">G</forename><surname>Finali</surname></persName></author><author><persName><forename type="first">M</forename><surname>Piccirilli</surname></persName></author><author><persName><forename type="first">C</forename><surname>Oliani</surname></persName></author><author><persName><forename type="first">Gl</forename><surname>Piccinin</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">14</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="523" to="536"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b9"><analytic><title level="a" type="main">Dopamine is a monoamine oxidase substrate in man</title><author><persName><forename type="first">V</forename><surname>Glover</surname></persName></author><author><persName><forename type="first">M</forename><surname>Sandler</surname></persName></author><author><persName><forename type="first">F</forename><surname>Owern</surname></persName></author><author><persName><forename type="first">Gj</forename><surname>Riley</surname></persName></author></analytic><monogr><title level="j">Nature</title><imprint><biblScope unit="volume">265</biblScope><biblScope unit="page" from="80" to="81"></biblScope><date type="published" when="1977"></date></imprint></monogr></biblStruct><biblStruct xml:id="b10"><analytic><title level="a" type="main">Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl</title><author><persName><forename type="first">V</forename><surname>Glove~</surname></persName></author><author><persName><forename type="first">Cj</forename><surname>Pycock</surname></persName></author><author><persName><forename type="first">M</forename><surname>Sandler</surname></persName></author></analytic><monogr><title level="j">Br J Pharmacol</title><imprint><biblScope unit="volume">80</biblScope><biblScope unit="page" from="141" to="148"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b11"><analytic><title level="a" type="main">A new rating scale for dementia syndromes</title><author><persName><forename type="first">C-G</forename><surname>Gottfries</surname></persName></author><author><persName><forename type="first">G</forename><surname>Brfine</surname></persName></author><author><persName><forename type="first">B</forename><surname>Gullberg</surname></persName></author><author><persName><forename type="first">G</forename><surname>Steen</surname></persName></author></analytic><monogr><title level="j">Arch Gerontol Geriatr</title><imprint><biblScope unit="volume">1</biblScope><biblScope unit="page" from="311" to="330"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct xml:id="b12"><analytic><title level="a" type="main">Selegiline in the treatment of Parkinson's disease</title><author><persName><forename type="first">Eh</forename><surname>Heinonen</surname></persName></author><author><persName><forename type="first">Uk</forename><surname>Rinne</surname></persName></author></analytic><monogr><title level="j">Acta Neurol Scand</title><imprint><biblScope unit="volume">80</biblScope><biblScope unit="page" from="103" to="111"></biblScope><date type="published" when="1989"></date></imprint></monogr><note>Suppl</note></biblStruct><biblStruct xml:id="b13"><analytic><title level="a" type="main">Pharmacokinetics and metabolism of selegiline</title><author><persName><forename type="first">Eh</forename><surname>Heinonen</surname></persName></author><author><persName><forename type="first">V</forename><surname>Myllylfi</surname></persName></author><author><persName><forename type="first">K</forename><surname>Sotaniemi</surname></persName></author><author><persName><forename type="first">R</forename><surname>Lammintausta</surname></persName></author><author><persName><forename type="first">J</forename><surname>Salonen</surname></persName></author><author><persName><forename type="first">M</forename><surname>Anttila</surname></persName></author><author><persName><forename type="first">M</forename><surname>Savijfirvi</surname></persName></author><author><persName><forename type="first">M</forename><surname>Kotila</surname></persName></author><author><persName><forename type="first">Uk</forename><surname>Rinne</surname></persName></author></analytic><monogr><title level="j">Acta Neurol Scand</title><imprint><biblScope unit="volume">80</biblScope><biblScope unit="page" from="93" to="99"></biblScope><date type="published" when="1989"></date></imprint></monogr><note>Suppl</note></biblStruct><biblStruct xml:id="b14"><analytic><title level="a" type="main">Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid</title><author><persName><forename type="first">J</forename><surname>Hildebrand</surname></persName></author><author><persName><forename type="first">F</forename><surname>Bourgeois</surname></persName></author><author><persName><forename type="first">M</forename><surname>Buyse</surname></persName></author><author><persName><forename type="first">S</forename><surname>Przedborski</surname></persName></author><author><persName><forename type="first">S</forename><surname>Goldman</surname></persName></author></analytic><monogr><title level="j">Acta Neurol Scand</title><imprint><biblScope unit="volume">81</biblScope><biblScope unit="page" from="427" to="430"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b15"><analytic><title level="a" type="main">Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma</title><author><persName><forename type="first">D</forename><surname>Hovevey-Sion</surname></persName></author><author><persName><forename type="first">Ij</forename><surname>Kopin</surname></persName></author><author><persName><forename type="first">Rw</forename><surname>Stull</surname></persName></author><author><persName><forename type="first">Ds</forename><surname>Goldstein</surname></persName></author></analytic><monogr><title level="j">Neuropharmacology</title><imprint><biblScope unit="volume">28</biblScope><biblScope unit="page" from="791" to="797"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct xml:id="b16"><analytic><title level="a" type="main">Plasma dihydroxy-phenylglycol (DHPG) in the in-vivo assessment of human neuronal norepinephrine metabolism</title><author><persName><forename type="first">Jl</forename><surname>Izzo</surname></persName></author><author><persName><surname>Jr</surname></persName></author><author><persName><forename type="first">Da</forename><surname>Thompson</surname></persName></author><author><persName><forename type="first">D</forename><surname>Horowitz</surname></persName></author></analytic><monogr><title level="j">Life Sci</title><imprint><biblScope unit="volume">37</biblScope><biblScope unit="page" from="1033" to="1038"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct xml:id="b17"><analytic><title level="a" type="main">Is the mesocortical dopaminergic system involved in Parkinson!s disease?</title><author><persName><forename type="first">F</forename><surname>Javoy-Agid</surname></persName></author><author><persName><forename type="first">Y</forename><surname>Agid</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">30</biblScope><biblScope unit="page" from="1326" to="1330"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct xml:id="b18"><analytic><title level="a" type="main">The possible mechanism of action of (-)-deprenyl in Parkinson's disease</title><author><persName><forename type="first">J</forename><surname>Knoll</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="177" to="198"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct xml:id="b19"><analytic><title level="a" type="main">Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease</title><author><persName><forename type="first">A</forename><surname>Mangoni</surname></persName></author><author><persName><forename type="first">Mp</forename><surname>Grassi</surname></persName></author><author><persName><forename type="first">L</forename><surname>Frattola</surname></persName></author><author><persName><forename type="first">R</forename><surname>Piolti</surname></persName></author><author><persName><forename type="first">S</forename><surname>Bassi</surname></persName></author><author><persName><forename type="first">A</forename><surname>Motta</surname></persName></author><author><persName><forename type="first">A</forename><surname>Marcone</surname></persName></author><author><persName><forename type="first">S</forename><surname>Smirne</surname></persName></author></analytic><monogr><title level="j">Eur Neurol</title><imprint><biblScope unit="volume">31</biblScope><biblScope unit="page" from="100" to="107"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b20"><analytic><title level="a" type="main">Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl</title><author><persName><forename type="first">E</forename><surname>Martignoni</surname></persName></author><author><persName><forename type="first">G</forename><surname>Bono</surname></persName></author><author><persName><forename type="first">F</forename><surname>Blandini</surname></persName></author><author><persName><forename type="first">E</forename><surname>Sinforiani</surname></persName></author><author><persName><forename type="first">P</forename><surname>Merlo</surname></persName></author><author><persName><forename type="first">G</forename><surname>Nappi</surname></persName></author></analytic><monogr><title level="j">J Neural Transm [PD-Sect]</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page" from="15" to="25"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b21"><analytic><title level="a" type="main">Brief information on an early phase-II study with deprenyl in demented patients</title><author><persName><forename type="first">E</forename><surname>Martini</surname></persName></author><author><persName><forename type="first">I</forename><surname>Pataky</surname></persName></author><author><persName><forename type="first">K</forename><surname>Szilfigyi</surname></persName></author><author><persName><forename type="first">V</forename><surname>Venter</surname></persName></author></analytic><monogr><title level="j">Pharmacopsychiatry</title><imprint><biblScope unit="volume">20</biblScope><biblScope unit="page" from="256" to="257"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b22"><analytic><title level="a" type="main">Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease</title><author><persName><forename type="first">G</forename><surname>Mckhan</surname></persName></author><author><persName><forename type="first">D</forename><surname>Drachman</surname></persName></author><author><persName><forename type="first">M</forename><surname>Folstein</surname></persName></author><author><persName><forename type="first">R</forename><surname>Katzman</surname></persName></author><author><persName><forename type="first">D</forename><surname>Price</surname></persName></author><author><persName><forename type="first">Em</forename><surname>Stadlan</surname></persName></author></analytic><monogr><title level="j">Neurology (NY)</title><imprint><biblScope unit="volume">34</biblScope><biblScope unit="page" from="939" to="944"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct xml:id="b23"><analytic><title level="a" type="main">Transmitter release modulated by alphaadrenoceptor antagonists in the rabbit mesenteric artery: a comparison between noradrenaline outflow and electrical activity</title><author><persName><forename type="first">S</forename><surname>Mishima</surname></persName></author><author><persName><forename type="first">H</forename><surname>Myahara</surname></persName></author><author><persName><forename type="first">H</forename><surname>Suzuki</surname></persName></author></analytic><monogr><title level="j">Br J Pharmacol</title><imprint><biblScope unit="volume">83</biblScope><biblScope unit="page" from="537" to="547"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct xml:id="b24"><analytic><title level="a" type="main">Selegiline in the treatment of mild to moderate Alzheimer-type dementia</title><author><persName><forename type="first">A</forename><surname>Monteverde</surname></persName></author><author><persName><forename type="first">P</forename><surname>Gnemmi</surname></persName></author><author><persName><forename type="first">F</forename><surname>Rossi</surname></persName></author><author><persName><forename type="first">A</forename><surname>Monterverde</surname></persName></author><author><persName><forename type="first">Gc</forename><surname>Finali</surname></persName></author></analytic><monogr><title level="j">Clin Ther</title><imprint><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="315" to="322"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b25"><analytic><title level="a" type="main">Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia</title><author><persName><forename type="first">Gl</forename><surname>Piccinin</surname></persName></author><author><persName><forename type="first">G</forename><surname>Finali</surname></persName></author><author><persName><forename type="first">M</forename><surname>Piccirilli</surname></persName></author></analytic><monogr><title level="j">Clin Neuropharmacol</title><imprint><biblScope unit="volume">13</biblScope><biblScope unit="page" from="147" to="163"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b26"><analytic><title level="a" type="main">On the mode of action of 1-deprenyl in the human central nervous system</title><author><persName><forename type="first">P</forename><surname>Riederer</surname></persName></author><author><persName><forename type="first">Mbh</forename><surname>Youdim</surname></persName></author><author><persName><forename type="first">Wd</forename><surname>Rausch</surname></persName></author><author><persName><forename type="first">W</forename><surname>Birkmayer</surname></persName></author><author><persName><forename type="first">K</forename><surname>Jellinger</surname></persName></author><author><persName><forename type="first">D</forename><surname>Seemann</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="217" to="226"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct xml:id="b27"><analytic><title level="a" type="main">Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of 1-deprenyl</title><author><persName><forename type="first">P</forename><surname>Riederer</surname></persName></author><author><persName><forename type="first">C</forename><surname>Konradi</surname></persName></author><author><persName><forename type="first">V</forename><surname>Schay</surname></persName></author><author><persName><forename type="first">E</forename><surname>Kienzl</surname></persName></author><author><persName><forename type="first">G</forename><surname>Birkmayer</surname></persName></author><author><persName><forename type="first">W</forename><surname>Danielczyk</surname></persName></author><author><persName><forename type="first">E</forename><surname>Sofic</surname></persName></author><author><persName><forename type="first">Mbh</forename><surname>Youdim</surname></persName></author></analytic><monogr><title level="j">Adv Neurol</title><editor>Yahr MD, Bergmann KJ</editor><imprint><publisher>Raven Press</publisher><publisher>Raven Press</publisher><biblScope unit="page" from="111" to="118"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b28"><analytic><title level="a" type="main">L-deprenyl treatment of on-off phenomena in Parkinson's disease</title><author><persName><forename type="first">Uk</forename><surname>Rinne</surname></persName></author><author><persName><forename type="first">T</forename><surname>Siirtola</surname></persName></author><author><persName><forename type="first">V</forename><surname>Sonninen</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">43</biblScope><biblScope unit="page" from="253" to="262"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct xml:id="b29"><analytic><title level="a" type="main">Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection</title><author><persName><forename type="first">M</forename><surname>Scheinin</surname></persName></author><author><persName><forename type="first">W-H</forename><surname>Chang</surname></persName></author><author><persName><forename type="first">Kl</forename><surname>Kirk</surname></persName></author><author><persName><forename type="first">M</forename><surname>Linnoila</surname></persName></author></analytic><monogr><title level="j">Anal Biochem</title><imprint><biblScope unit="volume">131</biblScope><biblScope unit="page" from="246" to="253"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b30"><analytic><title level="a" type="main">Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of a2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers</title><author><persName><forename type="first">M</forename><surname>Scheinin</surname></persName></author><author><persName><forename type="first">S</forename><surname>Karhuvaara</surname></persName></author><author><persName><forename type="first">P</forename><surname>Ojala-Karlsson</surname></persName></author><author><persName><forename type="first">A</forename><surname>Kallio</surname></persName></author><author><persName><forename type="first">M</forename><surname>Koulu</surname></persName></author></analytic><monogr><title level="j">Life Sci</title><imprint><biblScope unit="volume">49</biblScope><biblScope unit="page" from="75" to="84"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b31"><analytic><title level="a" type="main">A pilot study of low-dose L-deprenyl in Alzheimer's disease</title><author><persName><forename type="first">Ls</forename><surname>Schneider</surname></persName></author><author><persName><forename type="first">Ve</forename><surname>Pollock</surname></persName></author><author><persName><forename type="first">Mf</forename><surname>Zemansky</surname></persName></author><author><persName><forename type="first">Rp</forename><surname>Gleason</surname></persName></author><author><persName><forename type="first">R</forename><surname>Palmer</surname></persName></author><author><persName><forename type="first">B</forename><surname>Sloane</surname></persName></author></analytic><monogr><title level="j">J Geriatr Psychiatry Neurol</title><imprint><biblScope unit="volume">4</biblScope><biblScope unit="page" from="143" to="148"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b32"><analytic><title level="a" type="main">Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease</title><author><persName><forename type="first">T</forename><surname>Sunderland</surname></persName></author><author><persName><forename type="first">Pn</forename><surname>Tariot</surname></persName></author><author><persName><forename type="first">Rm</forename><surname>Cohen</surname></persName></author><author><persName><forename type="first">Pa</forename><surname>Newhouse</surname></persName></author><author><persName><forename type="first">Am</forename><surname>Mellow</surname></persName></author><author><persName><forename type="first">Ea</forename><surname>Mueller</surname></persName></author><author><persName><forename type="first">Dl</forename><surname>Murphy</surname></persName></author></analytic><monogr><title level="j">Psychopharmacology</title><imprint><biblScope unit="volume">91</biblScope><biblScope unit="page" from="293" to="296"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b33"><analytic><title level="a" type="main">Normetanephrine and metanephrine oxidized by both types of monoamine oxidase</title><author><persName><forename type="first">O</forename><surname>Suzuki</surname></persName></author><author><persName><forename type="first">T</forename><surname>Matsumoto</surname></persName></author></analytic><monogr><title level="j">Experimentia</title><imprint><biblScope unit="volume">41</biblScope><biblScope unit="page" from="634" to="636"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct xml:id="b34"><analytic><title level="a" type="main">L-Deprenyl in Alzheimer's disease</title><author><persName><forename type="first">Pn</forename><surname>Tariot</surname></persName></author><author><persName><forename type="first">Rm</forename><surname>Cohen</surname></persName></author><author><persName><forename type="first">T</forename><surname>Sunderland</surname></persName></author><author><persName><forename type="first">Pa</forename><surname>Newhouse</surname></persName></author><author><persName><forename type="first">D</forename><surname>Yount</surname></persName></author><author><persName><forename type="first">Am</forename><surname>Mellow</surname></persName></author><author><persName><forename type="first">H</forename><surname>Weingartner</surname></persName></author><author><persName><forename type="first">Ea</forename><surname>Mueller</surname></persName></author><author><persName><forename type="first">Dl</forename><surname>Murphy</surname></persName></author></analytic><monogr><title level="j">Arch Gen Psychiatry</title><imprint><biblScope unit="volume">44</biblScope><biblScope unit="page" from="427" to="433"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b35"><analytic><title level="a" type="main">Cognitive effects of L-deprenyl in Alzheimer's disease</title><author><persName><forename type="first">Pn</forename><surname>Tariot</surname></persName></author><author><persName><forename type="first">T</forename><surname>Sunderland</surname></persName></author><author><persName><forename type="first">H</forename><surname>Weingartner</surname></persName></author><author><persName><forename type="first">Dl</forename><surname>Murphy</surname></persName></author><author><persName><forename type="first">Ja</forename><surname>Welkowitz</surname></persName></author><author><persName><forename type="first">K</forename><surname>Thompson</surname></persName></author><author><persName><forename type="first">Rm</forename><surname>Cohen</surname></persName></author></analytic><monogr><title level="j">Psychopharmacology</title><imprint><biblScope unit="volume">91</biblScope><biblScope unit="page" from="489" to="495"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct xml:id="b36"><analytic><title level="a" type="main">The effect of deprenyl (selegiline) on the natural history of Parkinson's disease</title><author><persName><forename type="first">Jw</forename><surname>Tetrud</surname></persName></author><author><persName><forename type="first">Jw</forename><surname>Langston</surname></persName></author></analytic><monogr><title level="j">Science</title><imprint><biblScope unit="volume">245</biblScope><biblScope unit="page" from="519" to="522"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct xml:id="b37"><analytic><title level="a" type="main">Effect of deprenyl on the progression of disability in early Parkinson's disease</title></analytic><monogr><title level="m">The Parkinson Study Group</title><imprint><date type="published" when="1989"></date><biblScope unit="page" from="1364" to="1371"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b38"><monogr><title level="m" type="main">CSF monoamine metabolites during selegiline treatment</title><author><persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Heinonen</surname></persName></author><imprint></imprint></monogr></biblStruct><biblStruct xml:id="b39"><monogr><title level="m" type="main">The action of (-)deprenyl on monoamine turnover rate in rat brain Typical and atypical antidepressants: molecular mechanisms</title><author><persName><forename type="first">G</forename><surname>Zsilla</surname></persName></author><author><persName><forename type="first">J</forename><surname>Knoll</surname></persName></author><editor>Costa E, Racagni G</editor><imprint><date type="published" when="1982"></date><publisher>Raven Press</publisher><biblScope unit="page" from="211" to="217"></biblScope><pubPlace>New York</pubPlace></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001335 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001335 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:09AACF3CE7AC45D5646858190481A17203A07677
|texte= Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
}}
| This area was generated with Dilib version V0.6.23. |  |